Tocilizumab for treating mevalonate kinase deficiency and TNF receptor-associated periodic syndrome: a case series and literature review
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Tocilizumab for treating mevalonate kinase deficiency and TNF receptor-associated periodic syndrome: a case series and literature review ; volume:22 ; number:1 ; day:5 ; month:1 ; year:2024 ; pages:1-10 ; date:12.2024
Pediatric rheumatology ; 22, Heft 1 (5.1.2024), 1-10, 12.2024
- Urheber
-
Li, Yandie
Lu, Meiping
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12969-023-00952-2
- URN
-
urn:nbn:de:101:1-2024031822043524699040
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Li, Yandie
- Lu, Meiping
- SpringerLink (Online service)
Ähnliche Objekte (12)
A Pilot Study on Tocilizumab for Treating Refractory Adult-Onset Still’s Disease
![Effekte einer Tocilizumab-Therapie auf die Knochendichte, Marker des Knochenstoffwechsels und Aktivitätsparameter bei TNF-α [TNF-alpha] vortherapierter aktiver rheumatoider Arthritis](/assets/placeholder/searchResultMediaNoDigitisedMedia.png)
Effekte einer Tocilizumab-Therapie auf die Knochendichte, Marker des Knochenstoffwechsels und Aktivitätsparameter bei TNF-α [TNF-alpha] vortherapierter aktiver rheumatoider Arthritis
Tuberculosis in otherwise healthy adults with inherited TNF deficiency
Publisher Correction: A Pilot Study on Tocilizumab for Treating Refractory Adult-Onset Still’s Disease
Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency
Deficiency of PPP6C protects TNF-induced necroptosis through activation of TAK1
Tocilizumab-Induced Erythema Annulare Centrifugum
A pro‐inflammatory signalome is constitutively activated by C33Y mutant TNF receptor 1 in TNF receptor‐associated periodic syndrome (TRAPS)
A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial)
Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome
Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies
Tocilizumab : erstes zugelassenes Biologikum bei Riesenzellarteriitis
A Pilot Study on Tocilizumab for Treating Refractory Adult-Onset Still’s Disease
Effekte einer Tocilizumab-Therapie auf die Knochendichte, Marker des Knochenstoffwechsels und Aktivitätsparameter bei TNF-α [TNF-alpha] vortherapierter aktiver rheumatoider Arthritis
Tuberculosis in otherwise healthy adults with inherited TNF deficiency
Publisher Correction: A Pilot Study on Tocilizumab for Treating Refractory Adult-Onset Still’s Disease
Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency
Deficiency of PPP6C protects TNF-induced necroptosis through activation of TAK1
Tocilizumab-Induced Erythema Annulare Centrifugum
A pro‐inflammatory signalome is constitutively activated by C33Y mutant TNF receptor 1 in TNF receptor‐associated periodic syndrome (TRAPS)
A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial)
Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome
Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies
Tocilizumab : erstes zugelassenes Biologikum bei Riesenzellarteriitis
A Pilot Study on Tocilizumab for Treating Refractory Adult-Onset Still’s Disease
Effekte einer Tocilizumab-Therapie auf die Knochendichte, Marker des Knochenstoffwechsels und Aktivitätsparameter bei TNF-α [TNF-alpha] vortherapierter aktiver rheumatoider Arthritis
Tuberculosis in otherwise healthy adults with inherited TNF deficiency
Publisher Correction: A Pilot Study on Tocilizumab for Treating Refractory Adult-Onset Still’s Disease
Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency
Deficiency of PPP6C protects TNF-induced necroptosis through activation of TAK1
Tocilizumab-Induced Erythema Annulare Centrifugum
A pro‐inflammatory signalome is constitutively activated by C33Y mutant TNF receptor 1 in TNF receptor‐associated periodic syndrome (TRAPS)
A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial)
Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome
Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies